Resveratrol ameliorates depressive-like behavior in repeated corticosterone-induced depression in mice

Steroids

Volumn 101, Issue , 2015, Pages 37-42

  Ali, Syed Hamid ^a   Madhana, Rajaram Mohanrao ^a   Athira, K V ^a   Kasala, Eshvendar Reddy ^a   Bodduluru, Lakshmi Narendra ^a   Pitta, Sathish ^a   Mahareddy, Jalandhar Reddy ^a   Lahkar, Mangala ^a,b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b GAUHATI MEDICAL COLLEGE   (India)

Author keywords

BDNF; Corticosterone; Depressive like behavior; Hippocampus; HPA axis; Resveratrol

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; FLUOXETINE; RESVERATROL; ANTIDEPRESSANT AGENT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DRUG MECHANISM; FORCED SWIM TEST; HIPPOCAMPUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; STRESS; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM;

ANIMALIA; MUS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; DEPRESSION; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MALE; MICE; STILBENES;

EID: 84931264889     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2015.05.010     Document Type: Article

References (44)

1. D.G. Perahia, D. Quail, D. Desaiah, A.L. Montejo, and A.F. Schatzberg Switching to duloxetine in selective serotonin reuptake inhibitor non-and partial-responders: effects on painful physical symptoms of depression J Psychiatr Res 43 5 2009 512 518
2. C.B. Nemeroff The burden of severe depression: a review of diagnostic challenges and treatment alternatives J Psychiatr Res 41 3 2007 189 206
3. R.C. Kessler The costs of depression Psychiatr Clin North Am 35 1 2012 1 14
4. C. Mathers, D.M. Fat, and J.T. Boerma The global burden of disease: 2004 update 2008 World Health Organization
5. World Health Organization: Depression 2012 WHO Geneva 2013
6. A. Bartolomucci, and R. Leopardi Stress and depression: preclinical research and clinical implications PLoS One 4 1 2009 e4265
7. K. Martinowich, H. Manji, and B. Lu New insights into BDNF function in depression and anxiety Nat Neurosci 10 9 2007 1089 1093
8. D. Gupta, M. Radhakrishnan, and Y. Kurhe Effect of a novel 5-HT 3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice Steroids 96 2015 95 102
9. M.F. Juruena, A.J. Cleare, and C.M. Pariante The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression Rev Bras Psiquiatr 26 3 2004 189 201
10. D.F. Swaab, A.M. Bao, and P.J. Lucassen The stress system in the human brain in depression and neurodegeneration Ageing Res Rev 4 2 2005 141 194
11. S.A. Johnson, N.M. Fournier, and L.E. Kalynchuk Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor Behav Brain Res 168 2 2006 280 288
12. E.R. Kasala, L.N. Bodduluru, Y. Maneti, and R. Thipparaboina Effect of meditation on neurophysiological changes in stress mediated depression Complement Ther Clin Pract 20 1 2014 74 80
13. S. Watson, and P. Mackin HPA axis function in mood disorders Psychiatry 5 5 2006 166 170
14. J. Keller, B. Flores, R.G. Gomez, H.B. Solvason, H. Kenna, G.H. Williams, and A.F. Schatzberg Cortisol circadian rhythm alterations in psychotic major depression Biol Psychiatry 60 3 2006 275 281
15. N. Sonino, and G. Fava Psychosomatic aspects of Cushing's disease Psychother Psychosom 67 3 1997 140 146
16. M.J. Schaaf, J. de Jong, E.R. de Kloet, and E. Vreugdenhil Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone Brain Res 813 1 1998 112 120
17. Y. Zhao, R. Ma, J. Shen, H. Su, D. Xing, and L. Du A mouse model of depression induced by repeated corticosterone injections Eur J Pharmacol 581 1 2008 113 120
18. Q.Q. Mao, Z. Huang, X.M. Zhong, Y.F. Xian, and S.P. Ip Piperine reverses the effects of corticosterone on behavior and hippocampal BDNF expression in mice Neurochem Int 74 2014 36 41
19. N. Bouvier, T. Trenque, and H. Millart Development of antidepressant drugs. Experience and prospects Presse Med (Paris, France: 1983) 32 11 2003 519 522
20. P. Langcake, and R. Pryce The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury Physiol Plant Pathol 9 1 1976 77 86
21. G.J. Soleas, E.P. Diamandis, and D.M. Goldberg Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30 2 1997 91 113
22. C.A. de la Lastra, and I. Villegas Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications Biochem Soc Trans 35 Pt 5 2007 1156 1160
23. F. Zhang, J. Liu, and J.S. Shi Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation Eur J Pharmacol 636 1 2010 1 7
24. L. Wang, B. Waltenberger, E.M. Pferschy-Wenzig, M. Blunder, X. Liu, C. Malainer, T. Blazevic, S. Schwaiger, J.M. Rollinger, and E.H. Heiss Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review Biochem Pharmacol 92 1 2014 73 89
25. K.P. Bhat, and J.M. Pezzuto Cancer chemopreventive activity of resveratrol Ann N Y Acad Sci 957 1 2002 210 229
26. G. Tredici, M. Miloso, G. Nicolini, S. Galbiati, G. Cavaletti, and A. Bertelli Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Drugs Exp Clin Res 25 2-3 1998 99 103
27. A. Mobasheri, and M. Shakibaei Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis Ann N Y Acad Sci 1290 1 2013 59 66
28. M. Böttner, J. Christoffel, H. Jarry, and W. Wuttke Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on pituitary function in rats J Endocrinol 189 1 2006 77 88
29. Y. Xu, Z. Wang, W. You, X. Zhang, S. Li, P.A. Barish, M.M. Vernon, X. Du, G. Li, and J. Pan Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system Eur Neuropsychopharmacol 20 6 2010 405 413
30. S. Pitta, B.B. Augustine, E.R. Kasala, K. Sulakhiya, V. Ravindranath, and M. Lahkar Honokiol reverses depressive-like behavior and decrease in brain BDNF levels induced by chronic corticosterone injections in mice Pharmacognosy J 5 5 2013 211 215
31. Q.Q. Mao, Y.F. Xian, S.P. Ip, S.H. Tsai, and C.T. Che Long-term treatment with peony glycosides reverses chronic unpredictable mild stress-induced depressive-like behavior via increasing expression of neurotrophins in rat brain Behav Brain Res 210 2 2010 171 177
32. R. Porsolt, A. Bertin, and M. Jalfre Behavioral despair in mice: a primary screening test for antidepressants Arch Int Pharmacodyn Ther 229 2 1977 327 336
33. L. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology 85 3 1985 367 370
34. L. Lanfumey, R. Mongeau, C. Cohen-Salmon, and M. Hamon Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders Neurosci Biobehav Rev 32 6 2008 1174 1184
35. Ł.R. Drzyzga, A. Marcinowska, and E. Obuchowicz Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies Brain Res Bull 79 5 2009 248 257
36. A.D. Başterzi, K. Yazici, E. Aslan, N. Delialioʇlu, B. Taşdelen, Ş.T. Acar, and A. Yazici Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients Prog Neuropsychopharmacol Biol Psychiatry 33 2 2009 281 285
37. Q.Q. Mao, Z. Huang, S.P. Ip, Y.F. Xian, and C.T. Che Peony glycosides reverse the effects of corticosterone on behavior and brain BDNF expression in rats Behav Brain Res 227 1 2012 305 309
38. C. Pang, L. Cao, F. Wu, L. Wang, G. Wang, and Y. Yu The effect of trans-resveratrol on post-stroke depression via regulation of hypothalamus-pituitary-adrenal axis Neuropharmacology 2015 10.1016/j.neuropharm.2015.04.017
39. D. Liu, K. Xie, X. Yang, J. Gu, L. Ge, and X. Wang Resveratrol reverses the effects of chronic unpredictable mild stress on behavior, serum corticosterone levels and BDNF expression in rats Behav Brain Res 264 2014 9 16 10.1016/j.bbr.2014.01.039
40. J. Burns, T. Yokota, H. Ashihara, M.E. Lean, and A. Crozier Plant foods and herbal sources of resveratrol J Agric Food Chem 50 11 2002 3337 3340
41. I. Lekli, G. Szabo, B. Juhasz, S. Das, M. Das, E. Varga, L. Szendrei, R. Gesztelyi, J. Varadi, and I. Bak Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin Am J Physiol Heart Circ Physiol 294 2 2008 H859-H66
42. F. Li, Q. Gong, H. Dong, and J. Shi Resveratrol, a neuroprotective supplement for Alzheimer's disease Curr Pharm Des 18 1 2012 27 33
43. D.D. Lofrumento, G. Nicolardi, A. Cianciulli, F. De Nuccio, V. La Pesa, V. Carofiglio, T. Dragone, R. Calvello, and M.A. Panaro Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses Innate Immun 20 3 2014 249 260
44. S. Sale, R.D. Verschoyle, D. Boocock, D. Jones, N. Wilsher, K.C. Ruparelia, G. Potter, P.B. Farmer, W.P. Steward, and A.J. Gescher Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene Br J Cancer 90 3 2004 736 744